The addition of bevacizumab to the EGFR inhibitor erlotinib can prolong the progression free survival of EGFR mutated NSCLC patients by more than 6 months, and benefit more in EGFR L858R mutated patients, which provides further evidence for the targeted application of VEGFA/EGFR combination (Tanaka et al. 2020; Le et al. 2021). This evidence concerns the gene EGFR and non-small cell lung carcinoma.